reports
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 30,600 shares of Intellia’s common...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
AXTI AXT INC.
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
NTLA INTELLIA THERAPEUTICS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
RVMD INC.
AI REVOLUTION MEDICINES
STX C3.AI
GFS SEAGATE TECHNOLOGY HLDGS PLC
QBTS GLOBALFOUNDRIES INC
IONQ D-WAVE QUANTUM INC.
CART IONQ INC
MAPLEBEAR INC.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE...
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug ap...
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Inc: 1 director
A director at Intellia Therapeutics Inc sold after exercising options/sold 88,146 shares at 9.489USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's di...
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healt...
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, . A replay ...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2026, it awarded inducement grants to two new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 22,800 shares of Intellia’s common s...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing R...
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on December 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 12,600 shares of Intellia’s commo...
- Wedbush Research
VYGR VOYAGER THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
TSEM TOWER SEMICONDUCTOR LTD
SMCI SUPER MICRO COMPUTER
ZNTL INC.
TLS ZENTALIS PHARMACEUTICALS
STX TELOS
GFS SEAGATE TECHNOLOGY HLDGS PLC
GETY GLOBALFOUNDRIES INC
DDI GETTY IMAGES HOLDINGS INC
DOUBLEDOWN INTERACTIVE CO LTD
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Ne...
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baselineLonger-term safety data consistent with previously reported Phase 1 data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, ...
- Wedbush Research
VYGR VOYAGER THERAPEUTICS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
ZS ZSCALER INC.
REPL REPLIMUNE GROUP
STRO SUTRO BIOPHARMA
SMCI SUPER MICRO COMPUTER
TVTX INC.
RZLT TRAVERE THERAPEUTICS INC
TNGX REZOLUTE
STX TANGO THERAPEUTICS
HOWL INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
CMPX WEREWOLF THERAPEUTICS INC
ARTV GLOBALFOUNDRIES INC
PRME COMPASS THERAPEUTICS
BCAX ARTIVA BIOTHERAPEUTICS INC
MAZE PRIME MEDICINE INC
JBIO BICARA THERAPEUTICS INC.
CBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
CRESCENT BIOPHARMA INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ISR ISORAY
STRO SUTRO BIOPHARMA
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
ARTV ARTIVA BIOTHERAPEUTICS INC
PRME PRIME MEDICINE INC
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvo...
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for at least seven months (up to 32 months)Among the 11 patients who originally received a 50 mg dose in Phase 2, 10 were attack-free and LTP-free Continue to observe a well-tolerated safety profile with up to three years of ...
- Wedbush Research
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
CTMX CYTOMX THERAPEUTICS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
NFLX NETFLIX INC.
INOD INNODATA
PTGX PROTAGONIST THERAPEUTICS
NTLA INTELLIA THERAPEUTICS INC.
ANAB ANAPTYSBIO INC.
ROKU ROKU INC. CLASS A
RCKT ROCKET PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
HEAR TURTLE BEACH CORP.
STRO SUTRO BIOPHARMA
STTK SHATTUCK LABS
ABNB AIRBNB INC. CLASS A
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
PLTK PLAYTIKA HOLDING
TTD THE TRADE DESK
GLUE INC.
ATXS MONTE ROSA THERAPEUTICS INC
JANX ASTRIA THERAPEUTICS INC
YOU JANUX THERAPEUTICS INC
SOUN CLEAR SECURE INC
EWTX SOUNDHOUND AI INC
SYRE EDGEWISE THERAPEUTICS INC
NATL SPYRE THERAPEUTICS INC.
OS NCR ATLEOS CORPORATION
MAZE ONESTREAM INC
CBIO MAZE THERAPEUTICS INC
SNDK CRESCENT BIOPHARMA INC.
SANDISK CORP
- David Nierengarten
- Dennis Pak
- Martin Fan
Intellia Therapeutics Announces Third Quarter 2025 Financial Results a...
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo-z on Nov...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.